GlaxoSmithKline stands to generate £2bn over the next year from sales of pandemic flu vaccines, according to fresh figures released on Tuesday.

The company revealed details of its order book, saying it had now received requests from 73 governments totalling 440m doses of the pandemic vaccine, up from 291m doses at the start of August.